Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth/mini reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology. In addition, the journal also considers comprehensive studies and research advances pertaining food chemistry with pharmaceutical implication.
Areas of interest include:
DNA/protein engineering and processing
Omics (genomics, proteomics, metabolomics and systems biology)
Industrial bioprocesses for drug production and development
Special Issues devoted to crucial topics, providing the latest comprehensive information on cutting-edge areas of research and technological advances, are welcome.
Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
Manica Negahdaripour, Navid Nezafat, Reza Heidari, Nasrollah Erfani, Nasim Hajighahramani, Mohammad B. Ghoshoon, Eskandar Shoolian, Mohammad R. Rahbar, Sohrab Najafipour, Ali Dehshahri, Mohammad H. Morowvat and Younes Ghasemi*
Study of Anti-oxidant, Anti-inflammatory, Genotoxicity, and Antimicrobial Activities and Analysis of Different Constituents found in Rhizome Essential Oil of Curcuma caesia Roxb., Collected from North East India
Drs. Eric Betzig, Stefan W. Hell and William E. Moerner share the 2014 chemistry Nobel for the development of super-resolved fluorescence microscopy.
“The Royal Swedish Academy of Sciences has decided to award the 2014 Nobel Prize in Chemistry to Dr. Eric Betzig at Howard Hughes Medical Institute, Ashburn, U.S.A.; Professor Stefan Hell at Max Planck Institute for Biophysical Chemistry, Göttingen, and the German Cancer Research Center, Heidelberg, Germany; and Professor William Moerner at Stanford University, Stanford, U.S.A., for the development of super-resolved fluorescence microscopy.”
Much research effort was needed to realize that single-cell and single-molecule based approaches directly affect improvements in human health. However, many of these laboratory technologies are not available in a cheap and easy version. Single-molecule based fluorescence imaging and detection have the advantages of a small volume platform, digital analysis, elimination of processing steps, real-time measurements and automation of sample preparation. In 2015, Current Pharmaceutical Biotechnology will continue in this direction with quality papers that can be expected to trigger further investigations.
Drs. Eric Betzig and William E. Moerner also developed methods and biotechniques which have enabled the study of single molecules in ongoing chemical reactions in living cells. Because now it is possible to see individual macromolecules moving about in a living cell, we can study chemistry at a single-molecule level and in real life. And this is very important to chemistry because chemistry has traditionally been about studying a large number of molecules and the effect that they have. The journal Current Pharmaceutical Biotechnology has published on this research and has been at the forefront for over more than one decade. Curr. Pharm. Biotechnol. has published thematic issues, original research and review articles about the entirely new possibilities for chemistry and for biochemistry by eminent scientists from around the world, some examples:
Marcin Oplawski*, Konrad Dziobek, Nikola Zmarzły, Beniamin O. Grabarek, Robert Kiełbasiński, Przemysław Kieszkowski, Piotr Januszyk, Karol Talkowski, Michał Schweizer, Piotr Kras, Andrzej Plewka and Dariusz Boroń
Konrad Dziobek*, Marcin Opławski, Beniamin Grabarek, Nikola Zmarzły, Robert Kiełbasiński, Ewa Leśniak, Piotr Januszyk, Krzysztof Januszyk, Iwona Adwent, Dariusz Dąbruś, Przemysław Kieszkowski, Kamil Kiełbasiński, Agnieszka Kuś-Kierach and Dariusz Boroń
Dr. Nikolaos Labrou is a Full Professor with tenure and Director of the Enzyme Technology Lab at the Agricultural University of Athens, Greece. His research takes place where molecular enzymology, biochemistry, and pharmaceutical biotechnology meets and covers aspects of the entire range from pure to applied science. The principal area of his research program has been the mining, design, and exploitation of biocatalytic diversity. Dr. Labrou has authored more than 160 peer-reviewed articles in leading international journals and has edited six books. He is on the Editorial Board of several scientific journals and serves as a reviewer for multiple national and international grant agencies. He has established a strong global academic and industrial network and maintains international collaborations with several research groups at various institutions across the world.